Pacira BioSciences, Inc.
PCRX
$23.04
$0.200.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.92M | 1.64M | 5.43M | -4.85M | 4.81M |
| Total Depreciation and Amortization | 21.33M | 26.84M | 15.69M | 27.32M | 21.17M |
| Total Amortization of Deferred Charges | 577.00K | 576.00K | 682.00K | 872.00K | 867.00K |
| Total Other Non-Cash Items | 12.42M | -73.00K | 55.02M | 26.87M | 5.48M |
| Change in Net Operating Assets | -11.57M | 14.71M | -16.00M | -38.20M | 3.13M |
| Cash from Operations | 25.68M | 43.69M | 60.83M | 12.01M | 35.46M |
| Capital Expenditure | -2.72M | -218.00K | -3.87M | -2.70M | -8.55M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -335.00K | 0.00 | 0.00 | 0.00 | -16.70M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 22.50M | 19.55M | 47.48M | 64.86M | -379.00K |
| Cash from Investing | 19.44M | 19.33M | 43.61M | 62.16M | -25.63M |
| Total Debt Issued | -- | 0.00 | 101.00M | -- | -- |
| Total Debt Repaid | -5.00M | -5.00M | -306.24M | -3.75M | -2.81M |
| Issuance of Common Stock | 2.00K | 1.72M | 12.00K | 1.57M | -- |
| Repurchase of Common Stock | -54.40M | -48.39M | -50.05M | -55.32M | -181.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 17.00K | -2.20M | -- | -- |
| Cash from Financing | -59.40M | -51.65M | -257.48M | -57.51M | -2.99M |
| Foreign Exchange rate Adjustments | 38.00K | -414.00K | 133.00K | 204.00K | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.24M | 10.96M | -152.90M | 16.87M | 6.84M |